Sutro Biopharma Inc: Barclays raises target price to $57 from $56
STRO•Barclays raised its target price for Sutro Biopharma to $57 from $56.
Related News
Neuropace, Inc.: JPMorgan cuts to neutral from overweight; cuts target price to $9 from $20
NPCE•
Twist Bioscience Corporation: Guggenheim cuts target price to $150 from $212
TWST•
Pochettino to leave US team and take over as Man United head coach
MANU•
BioCryst study shows 30% drop in angioedema-related medical visits after switch to Orladeyo
BCRX•
Oil prices set for second weekly decline as Trump sticks with Iran blockade
USO•